After several days of insightful discussions, reconnecting with colleagues, and exchanging perspectives on the future of HEOR and RWE, we are now heading home from ISPOR 2026.
It has been a highly productive […]
A strong theme ran through Day 2:
Stakeholders have stopped debating whether real world evidence belongs at the decision table. The conversation has moved to how to generate RWE that is credible, transparent, and ready to inform real decisions.
Across sessions on […]
From a packed calendar of back-to-back meetings and new connections to wrapping up the night with a Dixieland band and great food with the athagoras Group […]
Starting Day 1 of ISPOR with the full team from the athagoras Group… We are looking forward to connecting with clients, new and old, colleagues and building new relationships.
Watch this space!
[…]
A strong research career often starts with curiosity and consistency.
We are happy to share that Sanjana has transitioned from intern to Research Analyst within Quantify Research’s Evidence Review and Synthesis team in India.
Since joining as an intern in October 2025, she […]
Quantify Research will be attending ISPOR 2026 in Philadelphia (17–20 May) as part of the athagoras Group.
Joining from Quantify:
• Puneet Kaushik
• Kelsi Smith
• Abraham Choong
TLV’s recent decision on Fabhalta provides further evidence of how Sweden applies higher acceptable ICERs in very rare conditions.
Fabhalta was assessed for a very rare, severe chronic kidney disease population. Following three-party negotiations, TLV’s base case, including the confidential agreement, […]
The Swedish HTA agency TLV has announced changes to the timeline and content of its upcoming guidance on reimbursement and pricing of medicines.
Key points from the update:
📍The previously communicated timeline has been postponed. The revised guidance will enter into force […]
Day 2 at SHEA highlighted a broader perspective: health economics extends well beyond traditional pharmacoeconomic frameworks.
Discussions included applications across:
📍social care alongside healthcare
📍the health economic value of green outdoor environments
Closer to our core areas, two themes stood out:
➡️ the continued importance […]
Day 1 in Lund highlighted a clear direction: global policy shifts are increasingly shaping local HTA realities.
External changes, including US MFN policy, are already influencing the pharmaceutical landscape beyond their origin.
Less than a year on, the impact feels well embedded.
At […]